Arovella Therapeutics Limited · ASX:ALA
Arovella Therapeutics — ShareCafe Small Cap "Hidden Gems" Webinar (July 2024)
17 slides from Arovella Therapeutics's conference presentation, Jul 19, 2024
Slide 1: Investor Webinar Presentation (ASX Release)
ASX: ALA Arovella Therapeutics Limited ACN 090 987 250 ASX Release 19 July 2024 INVESTOR WEBINAR PRESENTATION MELBOURNE, AUSTRALIA 19 July 2024: Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company focused on developing its invariant Natural Killer T (iNKT) cell therapy platform, is pleased
Slide 2: Notes to Editors: About Arovella Therapeutics
ASX: ALA Arovella Therapeutics Limited ACN 090 987 250 NOTES TO EDITORS: About Arovella Therapeutics Ltd Arovella Therapeutics Ltd (ASX: ALA) is a biotechnology company focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cance
Slide 3: Sharecafe Presentation
ASX:ALA For personal use only Sharecafe Presentation Dr Michael Baker July 2024
Slide 4: Disclaimer
Disclaimer 1. The information in this presentation does not constitute personal investment 4. Whilst this presentation is based on information from sources which are advice. The presentation is not intended to be comprehensive or provide all considered reliable, no representation or warranty, expres
Slide 5: Arovella's strengths
Arovella’s strengths Off-the-Shelf iNKT Lead Product Addressing Key Strong For personal use only Cell Platform Advancing to Clinic Unmet Need Leadership Group Developing off-the-shelf iNKT ALA-101, potential treatment Our iNKT cell platform is Leadership team and Board cell therapies to target blood
Slide 6: Financial overview
Financial overview Financial Snapshot ALA Price and Volume - 12 Months1 ASX CODE ALA $0.20 For personal use only Market capitalisation1 $173.5 million 40,000,000 $0.18 Shares on issue 1,050.5 million $0.16 52-week low / high1 $0.042 / $0.185 $0.14 30,000,000 Cash Balance (Mar 31, 2024)2 $15.31 milli
Slide 7: Recent cell therapy transactions
Recent cell therapy transactions1 Upfront Milestones Total deal Date Type of deal Acquirer/Licensee Target/Licensor Cell Type Stage (US$M) (US$M) value (US$M) Research May-24 T cell TBD $50 $550 $600 collaboration Dec-23 Acquisition T Cell Phase 1b $1,000 $200 $1,200 For personal use only Collaborat
Slide 8: Current CAR-T technology challenges and ALA's solution
Current CAR-T technology challenges ALA’s solution: One CAR-T product only treats the patient who supplied the T cells One CAR-iNKT batch from Manufacturing & supply a healthy donor treats For personal use only T cell chain costs are high multiple patients T cell Each T cells can be manufacturing co
Slide 9: Introducing invariant Natural Killer T (iNKT) cells
Introducing invariant Natural Killer T (iNKT) cells Bridging the innate and adaptive immune system For personal use only Innate Immunity Adaptive Immunity ASX:ALA 7
Slide 10: iNKT cells represent a next-generation cell therapy
iNKT cells represent a next-generation cell therapy Innate properties make them ideal for use in cell therapy Strong safety profile For personal use only Don’t cause graft versus host disease (GvHD) Innate Front line of the human Immunity immune system Bridge innate & adaptive immune responses
Slide 11: A differentiated position
A differentiated position T cell and NK cell sectors are competitive, iNKT cells remain untapped For personal use only T cell iNKT cell NK cell Companies with T cell, NK cell, or iNKT cell therapy programs. Source: Company analysis based on public information ASX:ALA 9
Slide 12: Clinic-ready manufacturing process developed
Clinic-ready manufacturing process developed Semi-automated process suitable for large-scale and late-phase clinical development TECHNOLOGY PRE-CLINICAL LENTIVIRUS MANUFACTURING FDA (IND) / PHASE 1 CLINICAL PHASE 2 CLINICAL PLATFORM For personal use only ACQUISITION CONFIRMATION MANUFACTURING TGA (C
Slide 13: Arovella's expanding pipeline
Arovella’s expanding pipeline For personal use only ASX:ALA 11
Slide 14: Upcoming milestones for FY2025
Upcoming milestones for FY2025 July July 2024 2025 For personal use only Complete cGMP manufacture for Phase 1 clinical trials Complete preparatory activities for Phase 1 study, preparation Arovella is funded to dose ALA-101 of regulatory dossier, engagement with clinical sites and KOLs patients
Slide 15: Summary
Summary Novel allogeneic Lead product progressing to CAR-iNKT cell platform clinical trials For personal use only iNKT cells serve as an excellent platform ALA-101, a potential treatment for CD19- to develop allogeneic, or “off-the-shelf”, expressing blood cancers, is being cell therapies to treat c
Slide 16: Thank You
ASX:ALA For personal use only Thank You Dr. Michael Baker CEO & Managing Director Email: investor@arovella.com Mobile: +61 403 468 187
Slide 17: Cell therapy deal references
Cell therapy deal references 1. https://www.astellas.com/en/news/28271 2. https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-to-acquire-gracell-furthering-cell-therapy-ambition-across-oncology-and- autoimmune-diseases.html For personal use only 3. https://www.astrazeneca.com/me
Arovella Therapeutics — ShareCafe Small Cap "Hidden Gems" Webinar (July 2024) on 6ix